CCCC
NASDAQC4 Therapeutics Inc.
Price$3.90+0.87 (+28.71%)
2026-03-052026-06-08
News · 26 weeks42-57%
2025-12-142026-06-07
Mix1690d
- SEC Filings7(44%)
- Other6(38%)
- Insider3(19%)
Latest news
25 items- INSIDERDirector Anderson Kenneth Carl exercised 1,070 shares at a strike of $2.11, increasing direct ownership by 2% to 69,300 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- PRC4 Therapeutics to Participate in Upcoming ConferencesWATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences. TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Management will participate in a virtual fireside chat on May 26, 2026, at 2:30 pm ET. 2026 Jefferies Global Healthcare Conference Management will participate in a fireside chat on June 3, 2026, at 8:45 am ET, taking place in New York, New York. Goldman Sachs 47th Annual Global Healthcare Conference Management will participate in 1x
- PRC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on May 18, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Ru
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form 10-Q filed by C4 Therapeutics Inc.10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsProgressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027 Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates Cash, Cash Equivalents and Marketable Securities of $268.3 Million as of March 31, 2026 with Cash Runway to the End of 2028 WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4
- SECSEC Form DEFA14A filed by C4 Therapeutics Inc.DEFA14A - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form DEF 14A filed by C4 Therapeutics Inc.DEF 14A - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche ((SIX: RO, ROP, OTCQX:RHHBY) to ad
- INSIDERSEC Form 4 filed by Anderson Kenneth Carl4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- INSIDERSEC Form 4 filed by Grogan Donna Roy4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
- PRC4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple MyelomaWATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed with cemsidomide, an oral IKZF1/3 degrader, in a Phase 1b trial evaluating cemsidomide and dexamethasone in combination with elranatamab (ELREXFIO®), an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody, for the treatment of relapsed/refractory multiple myeloma (RRMM). "Data from our Phase 1 trial support cemsidomide as a potential best-in-class, next-generation IKZF1/3 degrader and the initiation of this Phase 1b tri
- PRC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on March 9, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Li
- PRNext-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic
- SECSEC Form S-8 filed by C4 Therapeutics Inc.S-8 - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECSEC Form 10-K filed by C4 Therapeutics Inc.10-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- SECC4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
- PRC4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsCemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a cl
- PRC4 Therapeutics to Participate in Upcoming March ConferencesWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences. TD Cowen 46th Annual Healthcare Conference: Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts. Barclays 28th Annual Global Healthcare Conference: Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida. The live webcasts will be available on the Investors section o
- PRC4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple MyelomaEnrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). "Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety
- INSIDERChief Business Officer Boyle Scott N was granted 200,000 shares, converted options into 25,950 shares and covered exercise/tax liability with 9,004 shares, increasing direct ownership by 177% to 298,801 units (SEC Form 4)4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
CCCC FAQ
7 questionsWhat does C4 Therapeutics Inc. do?
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors...Where does CCCC stock trade?
C4 Therapeutics Inc. (CCCC) is listed on NASDAQ.What sector and industry is CCCC in?
C4 Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did C4 Therapeutics Inc. go public?
C4 Therapeutics Inc. (CCCC) completed its IPO in 2020.What are analysts saying about CCCC?
C4 Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2025-12-02. Recent price targets range from $400.00 to $1200.00.What companies are similar to CCCC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CCCC side-by-side with any of them on Quantisnow.How can I track CCCC on Quantisnow?
Quantisnow aggregates C4 Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCCC to receive live email and push alerts on every new disclosure.